Pengobatan antimalaria klorokuin sebagai terapi penyakit Systemic Lupus Erythematosus (SLE)
Author(s) -
Fadillah Maulidia
Publication year - 2020
Publication title -
wellness and healthy magazine
Language(s) - English
Resource type - Journals
eISSN - 2656-0062
pISSN - 2655-9951
DOI - 10.30604/well.82212020
Subject(s) - medicine , chloroquine , regimen , systemic lupus erythematosus , rheumatology , antimalarial agent , lupus erythematosus , immunology , disease , malaria , antibody
Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease that attacks various organs. Antimalarial agents are part of an immunomodulatory regimen that is used to cure patients with SLE. Not all antimalarial agents can be used in the treatment of lupus; This review lends to the study of the use of chloroquine. Overall, antimalarial drugs have many beneficial effects in patients with SLE, and have a good safety profile. According to the American College of Rheumatology (ACR) the diagnosis of SLE was originally established to be found at least 2 or more than 11 criteria. The classification degrees are divided into mild, moderate and severe SLE. The recommended use of base chloroquine 3.5-4.0 mg / kg BW / day (150-300 mg / day) is only used in mild SLE.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom